UK must act to reverse decline of industry clinical trials, says ABPI

Pharmaceutical industry body sets out steps to boost clinical trials, including regulation reform

The UK must act to reverse the decline of industry clinical trials, a group representing the pharmaceutical sector has warned.

The Association of the British Pharmaceutical Industry highlighted that the number of industry clinical trials has dropped in the UK. Phase 3 trial activity—those with new medicines closest to market—are particularly affected, with their number plummeting by 48 per cent since 2017, according to ABPI data.